AbbVie has officially waved the white flag on the cancer drug that triggered its $5.8 billion buyout of Stemcentryx a few years ago.
North Chicago, IL-based AbbVie (NYSE: ABBV) said that rovalpituzumab tesirine, or Rova-T, failed another clinical trial—this time a Phase 3 study, MERU, testing the drug as a maintenance therapy in patients with newly diagnosed small cell lung cancer (SCLC).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,